Your parents probably taught you that there are a few bad apples in every bunch, and those in the business world discover this sooner than later.
You’ve worked extremely hard, crafting your entrepreneurial dream and doing it with integrity and respect. Then you look over your shoulder, and the spoilers are there trying to muddy your good name and business. Jealousy and fear of competition are just a couple of reasons why you could be targeted, but you can successfully fight back. SearchCleanup.com can effectively remove the negative information about you and clean up your online reputation.
Here are also five excellent tips by Forbes.com on taking the high road when your reputation matters:
1. Stay Out Of The Pig Pen Don’t jump in and get muddy and start rambling on social media. Allow your better judgment and good character to speak volumes. Try and keep your temper in check.
2. Tell Customers You’re In It For The Long Haul. It’s business as usual, and that’s what you want to express to your customer base. Ensure the client that nothing is changing and that service has always been exceptional and will remain as such.
3. Offer Extra Value To Overshadow The Gossip. Go above and beyond what’s normal in your business and feature better content, product and service to your customers. The client likes being pampered and would choose superb value any day over rumors and other nonsense.
4. Ask For Help From Those Who Have Been Under Fire. Don’t retreat and hide under a rock, because you are not alone. Many entrepreneurs have been in your situation and can offer intelligent advice to weather out the storm. Plus, it’s okay to vent.
5. It’s All About The ‘Why’ Factor. Don’t ever forget why you established your company. You became an entrepreneur for a reason, so let that sound rationality be your guide. Stay focused and keep allowing your brand to evolve.
Your fine name and company can be restored, and SearchCleanup.com is another way to remove negative reviews and instantly clean up your search results.
Follow Search Cleanup on Twitter to stay up-to-date.
Helane Morrison works for a renowned advisory firm based in San Francisco. At Hall Capital Partners, she is the chief compliance officer. I suppose that in the company’s executive committee, Helane is regarded as one of the brilliant minds.
Helane recalls that people lost trust with the financial institutions because of the adverse effects of the 2008 financial crash. They could not entrust banks with their cash. After this phase, Hall has been consistently involved in rescuing the public by enforcing integrity, accountability and compliance of various regulations on any transactions made by financial institutions. Her assertive nature has had positive effects on the compliance field. Her hard work has improved operations at Hall Capital.
Morrison asserts that all the investments made by Hall capital on behalf of their clients have been solid and ethical. Helane works with a committed team of professionals. These experts must investigate any brokerage firm, mutual fund and financial institution that the firm chooses to work with before they can be permitted to handle client’s money. Helane’s enforcement staffs are vigilant on any transaction. When an anomaly arises, these members of staff jump into action and enforce disciplinary actions where they are due. These actions include correction practices and pressing of criminal charges against an individual or corporation. I believe that Helane’s success is anchored on her firmness and willingness to safeguard clients’ interests. This information was originally reported on Hackronym.
Before she secured her position at Hall Capital, Helane served as a regional director for the Securities and Exchange Commission (SEC). She was in charge of the San Francisco office. Previously, she worked as a district administrator. Given that these roles are demanding, I believe that her resilience resulted in her successful execution of her duties in Northern California. She was also in charge of 5 Northwest States. Her prime duties were securities enforcement, overseeing regulatory matters and litigation. It is my view that Helane’s interpersonal skills are excellent. This is because she represented the SEC in different functions including financial communities, legal businesses, new media and government agencies.
After graduating from the university, Helane was recruited by Howard, Rice, Nemerovski, Canady, Falk & Rabkin. She practiced law for 10 years. Out of the 10 years, Helane served as a partner of the law firm for over 5 years. Her primary duties were business litigation, defending private securities actions and deliberating on SEC matters. She also made progress in undertaking comprehensive internal corporate investigations. Notably, Helane worked as a law clerk before switching to private practice. In this position, she served Hon. Richard Posner and Justice Harry Blackmun. These justices worked in the Court of Appeals for the Seventh Circuit and Supreme Court respectively. This information was originally published on Hall Capital’s website.
I’ve always been interested in medical research. So I was understandably fascinated to see a recent legal dispute between Laidlaw & Company and Relmada Therapeutics. It’s not often that one sees a contentious legal battle between an investment bank and a clinical-stage medical research company. But this has progressed far enough at this point to even involve a temporary restraining order and associated injunction against Laidlaw.
U.S. Federal Court Issues Temporary Restraining Order Against Laidlaw & Company And Its Principals Matthew Eitner And James Ahern
On looking into it the nature of the case became far more clear. I’d known on an intellectual level that clinical testing of medicines was a costly process. It involves large sums of money to keep research studies going. And it’s always something of a gamble whether they’ll even be able to offer up any real returns. Even if a medicine makes it to the market it will often need to bring something special to the table in order to compete with current brands. And there’s always a good chance that it won’t actually make it to market in the first place. So it’s a bit more understandable why an investment company might want to take a more active role in the process.
Ultimately, I decided that my opinion would have to be decided by the nature of Laidlaw itself. And the morality of a company is often best decided by looking at the people who run it. In the case of Laidlaw, that’s Matthew Eitner and James Ahern. They certainly haven’t been with the company from the start, given that Laidlaw was founded in 1842. But they are very strongly associated with the company on the site itself. It’s an admirable level of pride in one’s company to so strongly tie one’s reputation to it.
And the relation between Matthew Eitner and James Ahern and Laidlaw is actually what dramatically raised my opinion of it. Both men have a strong history of altruistic endeavors involving medical care. And really, they have a strong history of altruistic gestures in general. A company is ultimately guided by the sense of moral and ethical responsibility of the people at the top. And the people at the top of Laidlaw seem like genuinely good people.
Clay Siegall is the current chairperson, president and chief executive officer at Seattle Genetics, a biotechnology company that develops antibody-based therapies for the treatment of cancer. Clay Siegall co-founded the company in the year 1998. Siegall is a scientist by training, having studied at the University of Maryland and attained a Bachelor’s of Science in Zoology. He then proceeded to the George Washington University for a Doctor of Philosophy in Genetics. With a background in science, he built Seattle Genetics on scientific innovation, research and drug development with the aim of helping patients. He has guided the company to be a leader in developing antibody-drug conjugates (ADCs) that are used in the treatment of cancer.
Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript
Under his leadership, Seattle Genetics has entered into various strategic licenses for the ADC technology and has been able to generate more than $300 million. The strategic licenses are with companies like GlaxoSmithKline, AbbVie, and Genentech amongst others. With the use of Seattle Genetics technology, there are more than 20 ADCs in clinical development. Clay Siegall helped to raise over $675 million for the company through various money raising activities such as public and private funding.
Before co-founding Seattle Genetics, Clay worked at the National Cancer Institute, National Institutes of Health from 1988 to 1991, and then he went to Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. He was on the board of directors of Aldor Bio-Pharmaceuticals and Washington Biotechnology and Biomedical Association.
Seattle Genetics has had good results with the recent second quarter results showing that the company made $95.4 million. This included record ADCETRIS sales worth $66.2 million, which is a 20% increase compared to the previous financial year, the second quarter of 2015. The company is confident that they will achieve their ADCETRIS net sales target for the year 2016 in the U.S and Canada. The projected net sales are projected to be between $255 million and $275 million. Seattle Genetics takes pride in the fact that ADCETRIS has been used in the treatment of more than 15,000 lymphoma patients throughout the world.